BeeCure, a Hollywood-based skincare and wound care brand developed by SanMelix Laboratories, Inc., has successfully closed a $1 million pre-seed funding round, providing new capital to support commercialization, product development, and market expansion.
The funding milestone was announced on November 11 by Capital Q Ventures, a Florida-based investment firm that participated as the final investor in the round. The investment represents another example of emerging healthcare and life sciences companies attracting early-stage capital in South Florida.
Bringing Science and Nature Together
Founded by Diana Sabacinski and Dr. Kenneth Sabacinski, BeeCure develops specialized skincare products featuring proprietary formulations made with buckwheat honey.
The company's products are designed to soothe, moisturize, and support sensitive or irritated skin, including skin affected by radiation therapy and laser treatments.
BeeCure's origins are rooted in Dr. Sabacinski's experience working with patients facing challenging diabetic wounds. That clinical background helped inspire the development of formulations combining naturally derived ingredients with modern skincare research.
Operating under SanMelix Laboratories, the company is pursuing opportunities in both specialized consumer skincare and advanced wound care, positioning itself at the intersection of healthcare innovation and consumer wellness.
$1 Million Investment Fuels Commercial Growth
The newly completed pre-seed round is expected to help BeeCure strengthen its commercial operations and accelerate its next phase of growth.
According to the funding announcement, the company plans to direct capital toward expanding sales and distribution, increasing marketing efforts, advancing product development, and strengthening operational infrastructure.
Capital Q Ventures, headquartered in Maitland, Florida, participated in completing the financing round. The firm focuses on supporting growing businesses through investment capital, strategic planning, and operational expertise.
"Successfully closing our $1 million pre-seed round is an important milestone for SanMelix Laboratories and the BeeCure® brand," said Steve Weinstein, CEO of BeeCure®. "With this funding and the continued support of Capital Q® Ventures, we are focused on advancing our commercialization strategy, expanding our reach, and building on the opportunities ahead."
From the investor's perspective, BeeCure's specialized product positioning and commercialization strategy were important factors in the investment.
"BeeCure® is addressing a distinct need in specialized skincare with a differentiated product platform," said Michael "Q" Quatrini, Founder and CEO of Capital Q® Ventures. "Our investment reflects our confidence in the company's direction and our commitment to supporting the team as it advances commercialization and expands its market presence."
For BeeCure, the financing comes at an important stage as the company works to build greater market awareness, establish additional commercial relationships, and position its specialized skincare solutions for broader adoption.
Early Commercial Traction and Market Opportunity
BeeCure enters its next growth phase with early evidence of commercial activity. According to historical financial information filed with the U.S. Securities and Exchange Commission, SanMelix Laboratories reported approximately $49,228 in net revenue for 2024, compared with $7,904 in 2023.
While the figures reflect an early-stage business, the increase demonstrates the company's initial progress in bringing its products to market. The company has also reported expanding distribution to medical offices and hospitals, securing a white-label agreement, and participating in an initiative to include its products in approximately 25,000 National Breast Cancer Foundation Hope Kits in 2025.
These developments illustrate BeeCure's efforts to establish a presence in specialized skincare channels while exploring opportunities to reach healthcare providers and consumers. Its longer-term opportunity may extend into advanced wound care, although the company's existing cosmetic skincare products should be distinguished from medical treatments that require additional clinical validation and regulatory authorization.
Building South Florida's Life Sciences Ecosystem
BeeCure's funding announcement adds to the growing diversity of South Florida's innovation economy. While much of the region's venture capital attention has centered on financial technology, artificial intelligence, and enterprise software, healthcare innovation and life sciences continue to represent important opportunities for entrepreneurship and investment.
Companies such as BeeCure demonstrate how specialized product development, clinical expertise, and commercial partnerships can create new pathways for businesses emerging from the region. The company's Broward County headquarters also reinforces the geographic breadth of South Florida's entrepreneurial activity, extending beyond the region's more established startup hubs.
For investors, BeeCure represents a different type of early-stage opportunity: a product-focused business seeking to translate specialized formulations and early commercial relationships into a scalable enterprise.
What's Next for BeeCure?
With its $1 million pre-seed round complete, BeeCure's next challenge will be converting additional capital into sustained commercial growth. Expanding distribution, building consumer and healthcare-provider awareness, strengthening strategic partnerships, and advancing new products will likely play central roles in the company's development.
Led by CEO Steve Weinstein, alongside co-founders Diana and Dr. Kenneth Sabacinski, the company is positioned to pursue additional opportunities in specialized skincare and related healthcare markets.
As South Florida's innovation ecosystem continues to mature, BeeCure's progress offers another example of locally based entrepreneurs working to bring differentiated healthcare products to market. For South Florida's venture and innovation community, the funding underscores the potential for early-stage investment to support commercialization across an increasingly diverse range of industries.


Hollywood, Florida-based BeeCure, a specialized skincare brand developed by SanMelix Laboratories, has closed a $1 million pre-seed funding round with support from Capital Q Ventures. The investment will accelerate commercialization, expand distribution, and advance product development, highlighting South Florida's growing life sciences and healthcare innovation ecosystem.